Monday , December 6 2021

[메디파나뉴스]In Tuzeo, the EASD demonstrated glycemic control of the patient's compliance with the insulin dose


Sanofi-aventis Korea In the first week of October in the EASD annual conference, Korea announced its next-generation long-term basal insulin TJEZO Solostar (ingredient name: insulin glucose, recombination 300 U / ml). The results of the control study have been published and it has been shown that Patients who label their teeth may have more effective glucose control than patients who are given appropriate supervision.

According to the "TAKE CONTROL" study, in patients with mean glycosylated hemoglobin (HbA1c) reaching the recommended blood glucose concentration of less than 7%, patients with self-contained patients were found to be greater than those who are in primary care care . In addition, patients (67% vs. 58%) achieved glucose in the blood at night (fasting) without hyperglycaemia (<3.0 mmol / L) or severe hypoglycaemia requiring medical attention.

During the study, the degree of psychological decline in both groups was similar and the number of patients reported to have a high psychological burden after 24 weeks was lower in patients who received the appropriate dose than those who were responsible for 8.5% versus 12, 2%)

David Russell Jones from the TAKE CONTROL study, presented at the Royal Surry County Hospital, Surrey, UK. "Many diabetics are experiencing hypoglycaemia, which is a major barrier to continued treatment," said the TAKE CONTROL study. A basal insulin such as Tuzeo has recently been developed to help patients control their blood sugar levels better. "

At the same time, the TAKE CONTROL study was conducted in 631 adult type 2 diabetic patients whose blood glucose levels were not adequately controlled during 24 weeks of treatment with Tozeol. We compared the efficacy and safety of Tuzeo when the patient titrated himself and when the person responsible was treated.

<© 2018 메디파나뉴스, 무단 전재 및 배포금지>"Korean Medicines News Center" MEDIPANA NEWS

Source link